Optimization of Tumor Treating Fields (TTFields) Frequency and Treatment Duration in Colorectal Cancer Cells

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-05-19 DOI:10.1002/cam4.70976

Menglan Liu, Zhaoran Su, Paul-Philipp Hagemann, Malte Fischer, Michael Linnebacher

{"title":"Optimization of Tumor Treating Fields (TTFields) Frequency and Treatment Duration in Colorectal Cancer Cells","authors":"Menglan Liu, Zhaoran Su, Paul-Philipp Hagemann, Malte Fischer, Michael Linnebacher","doi":"10.1002/cam4.70976","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Tumor Treating Fields (TTFields), a novel anticancer therapy using intermediate frequency and low-intensity alternating electric fields, has demonstrated efficacy in various cancers, but its application in CRC remains underexplored.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To determine the optimal frequency and treatment duration of TTFields therapy for CRC through in vitro experiments.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Four human CRC cell lines (2 MSI: HROC110 T1 M7, HROC285 T0 M2; 2 MSS: HROC450, HROC463) were treated using the inovitro TTFields system. Frequencies (100, 200, 300 kHz) and daily exposure durations (16, 20, 24 h/day) were varied. Cell viability was assessed after 72 h using crystal violet staining and spectrophotometry. Data were analyzed using <i>t</i>-tests or ANOVA, with <i>p</i> < 0.05 considered statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>TTFields significantly reduced cell viability at all tested frequencies. The 100 kHz frequency yielded the most pronounced effects, especially in MSI cell lines (<i>p</i> < 0.001). Treatment duration of 24 h/day led to the greatest viability reduction across all cell lines (<i>p</i> < 0.01), while 16 h/day and 20 h/day showed comparatively weaker effects.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study demonstrates that TTFields effectively reduce CRC cell viability, supporting their therapeutic potential. Further studies are needed to understand their mechanisms and synergy with existing treatments</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 10","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70976","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70976","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide. Tumor Treating Fields (TTFields), a novel anticancer therapy using intermediate frequency and low-intensity alternating electric fields, has demonstrated efficacy in various cancers, but its application in CRC remains underexplored.

Objective

To determine the optimal frequency and treatment duration of TTFields therapy for CRC through in vitro experiments.

Methods

Four human CRC cell lines (2 MSI: HROC110 T1 M7, HROC285 T0 M2; 2 MSS: HROC450, HROC463) were treated using the inovitro TTFields system. Frequencies (100, 200, 300 kHz) and daily exposure durations (16, 20, 24 h/day) were varied. Cell viability was assessed after 72 h using crystal violet staining and spectrophotometry. Data were analyzed using t-tests or ANOVA, with p < 0.05 considered statistically significant.

Results

TTFields significantly reduced cell viability at all tested frequencies. The 100 kHz frequency yielded the most pronounced effects, especially in MSI cell lines (p < 0.001). Treatment duration of 24 h/day led to the greatest viability reduction across all cell lines (p < 0.01), while 16 h/day and 20 h/day showed comparatively weaker effects.

Conclusion

Our study demonstrates that TTFields effectively reduce CRC cell viability, supporting their therapeutic potential. Further studies are needed to understand their mechanisms and synergy with existing treatments

查看原文本刊更多论文

结直肠癌细胞肿瘤治疗场（TTFields）频率和治疗时间的优化

结直肠癌（Colorectal cancer， CRC）是全球最常见的恶性肿瘤之一。肿瘤治疗电场（Tumor treatment Fields, TTFields）是一种使用中频低强度交变电场的新型抗癌疗法，已在多种癌症中显示出疗效，但其在结直肠癌中的应用仍有待探索。目的通过体外实验确定TTFields治疗结直肠癌的最佳频率和治疗时间。方法4株人结直肠癌细胞系(2 MSI: HROC110 T1 M7, HROC285 T0 M2；2个MSS: HROC450， HROC463)用体外TTFields系统处理。频率（100、200、300 kHz）和每日暴露时间（16、20、24小时/天）各不相同。72h后用结晶紫染色和分光光度法测定细胞活力。数据分析采用t检验或方差分析，p <； 0.05认为有统计学意义。结果TTFields在所有测试频率下显著降低细胞活力。100 kHz频率产生了最显著的效果，特别是在MSI细胞系中（p < 0.001）。处理时间为24 h/d时，各细胞系活力降低幅度最大（p < 0.01），处理时间为16 h/d和20 h/d时影响相对较弱。结论TTFields可有效降低结直肠癌细胞活力，支持其治疗潜力。需要进一步的研究来了解它们的机制和与现有治疗的协同作用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.